Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMD NASDAQ:ANEB NASDAQ:APLT NYSEAMERICAN:MTNB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$1.73-3.9%$1.90$1.26▼$4.50$15.34M2.4166,730 shs22,117 shsANEBAnebulo Pharmaceuticals$0.40-0.2%$0.44$0.01▼$3.42$16.11M-1.8841,876 shs100 shsAPLTApplied Therapeutics$0.10$0.10$0.09▼$1.50$15.86M2.087.28 million shsN/AMTNBMatinas Biopharma$0.64+3.1%$0.67$0.48▼$3.09$3.99M1.6768,658 shs52,415 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos-3.89%-8.13%-32.42%+24.46%-31.82%ANEBAnebulo Pharmaceuticals0.00%+1.18%-14.13%-55.46%-73.13%APLTApplied Therapeutics0.00%0.00%0.00%+0.00%-72.46%MTNBMatinas Biopharma+3.15%+6.36%-12.06%+14.57%-33.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$1.73-3.9%$1.90$1.26▼$4.50$15.34M2.4166,730 shs22,117 shsANEBAnebulo Pharmaceuticals$0.40-0.2%$0.44$0.01▼$3.42$16.11M-1.8841,876 shs100 shsAPLTApplied Therapeutics$0.10$0.10$0.09▼$1.50$15.86M2.087.28 million shsN/AMTNBMatinas Biopharma$0.64+3.1%$0.67$0.48▼$3.09$3.99M1.6768,658 shs52,415 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos-3.89%-8.13%-32.42%+24.46%-31.82%ANEBAnebulo Pharmaceuticals0.00%+1.18%-14.13%-55.46%-73.13%APLTApplied Therapeutics0.00%0.00%0.00%+0.00%-72.46%MTNBMatinas Biopharma+3.15%+6.36%-12.06%+14.57%-33.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 1.00SellN/AN/AANEBAnebulo Pharmaceuticals 1.50ReduceN/AN/AAPLTApplied Therapeutics 1.67Reduce$1.00870.87% UpsideMTNBMatinas Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MTNB, ANEB, AIMD, and APLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026AIMDAinos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026AIMDAinos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$120K122.83N/AN/A$1.29 per share1.34ANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.28 per shareN/AAPLTApplied Therapeutics$1M15.86N/AN/A$0.49 per share0.21MTNBMatinas Biopharma$1.10M3.74N/AN/A$0.75 per share0.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.77M-$2.89N/AN/AN/A-11,912.10%-160.55%-62.29%N/AANEBAnebulo Pharmaceuticals-$8.48M-$0.19N/AN/AN/AN/A-74.57%-68.96%N/AAPLTApplied Therapeutics-$105.62M-$0.10N/AN/AN/AN/A-340.84%-175.00%N/AMTNBMatinas Biopharma-$10.35M-$3.89N/AN/AN/AN/A-193.02%-124.09%N/ALatest MTNB, ANEB, AIMD, and APLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026AIMDAinosN/A-$0.41N/A-$0.41N/AN/A5/8/2026Q1 2026MTNBMatinas BiopharmaN/A-$0.30N/A-$0.30N/AN/A3/31/2026Q4 2025MTNBMatinas BiopharmaN/A-$0.26N/A-$0.26N/AN/A3/30/2026Q4 2025AIMDAinosN/A-$0.85N/A-$0.85N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/AANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AAPLTApplied TherapeuticsN/AN/AN/AN/AN/AMTNBMatinas BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos1.580.550.50ANEBAnebulo PharmaceuticalsN/A6.246.24APLTApplied TherapeuticsN/A0.960.96MTNBMatinas BiopharmaN/A1.321.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/AANEBAnebulo Pharmaceuticals28.40%APLTApplied Therapeutics98.31%MTNBMatinas Biopharma11.77%Insider OwnershipCompanyInsider OwnershipAIMDAinos9.79%ANEBAnebulo Pharmaceuticals80.60%APLTApplied Therapeutics1.60%MTNBMatinas Biopharma4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos408.52 million7.69 millionNot OptionableANEBAnebulo Pharmaceuticals440.79 million7.91 millionNot OptionableAPLTApplied Therapeutics30153.96 million151.50 millionOptionableMTNBMatinas Biopharma306.41 million6.11 millionN/AMTNB, ANEB, AIMD, and APLT HeadlinesRecent News About These CompaniesMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing ...June 27 at 3:06 AM | caledonianrecord.comCMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain ComplianceJune 26 at 5:15 PM | globenewswire.comMatinas BioPharma Holdings, Inc.April 8, 2026 | edition.cnn.comMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsApril 3, 2026 | finance.yahoo.comMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsApril 3, 2026 | globenewswire.comMatinas BioPharma Holdings, Inc. (MTNB) Restructures Amid Challenges, Focuses on Oral Antifungal MAT2203September 24, 2025 | msn.comMTNB Matinas BioPharma Holdings, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comMatinas BioPharma Holdings, Inc. (MTNB) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comKalkine Matinas BioPharma Surges Amid NYSE Composite Market MomentumJune 7, 2025 | kalkinemedia.comKMatinas BioPharma amends bylaws, updates on officer agreementsMay 4, 2025 | investing.comMatinas BioPharma files to sell 16.9M shares of common stock for holdersApril 24, 2025 | markets.businessinsider.comMatinas BioPharma secures shareholder nods on key proposalsApril 6, 2025 | investing.comMatinas BioPharma announces board chairman’s departureMarch 16, 2025 | investing.comMatinas BioPharma appoints Murphy, Neugeboren to board of directorsMarch 11, 2025 | markets.businessinsider.comMatinas BioPharma Appoints Seasoned Biotech Leaders to Board of DirectorsMarch 11, 2025 | finance.yahoo.comMatinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of DirectorsFebruary 13, 2025 | globenewswire.comMatinas BioPharma announces board member retirementFebruary 11, 2025 | msn.comMatinas BioPharma Appoints Evelyn D’An as Independent Director and Audit Committee ChairFebruary 9, 2025 | nasdaq.comMatinas BioPharma appoints Evelyn D’An to board of directorsFebruary 7, 2025 | markets.businessinsider.comMatinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee ChairFebruary 7, 2025 | finance.yahoo.comMedia Sentiment Over TimeMTNB, ANEB, AIMD, and APLT Company DescriptionsAinos NASDAQ:AIMD$1.73 -0.07 (-3.89%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$1.78 +0.05 (+2.89%) As of 06/26/2026 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Anebulo Pharmaceuticals NASDAQ:ANEB$0.40 0.00 (-0.20%) As of 06/26/2026 09:31 AM EasternAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Applied Therapeutics NASDAQ:APLT$0.10 0.00 (0.00%) As of 06/26/2026Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Matinas Biopharma NYSEAMERICAN:MTNB$0.64 +0.02 (+3.15%) As of 06/26/2026 04:10 PM EasternMatinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
